Klor-Con M10 (potassium chloride)

Dosage of potassium supplements is usually expressed as mEq of potassium and depends on the requirements of the individual patient. The normal adult daily requirement and the usual dietary intake of potassium is 40-80 mEq; infants may require 2-3 mEq/kg or 40 mEq/m2 daily. Potassium replacement requirements can be estimated only by initial clinical condition and response, ECG monitoring, and/or plasma potassium determinations. Prophylactic administration of potassium supplements may be necessary in some patients in order to maintain plasma potassium concentration above 3.0 mEq/L. The average oral dosage of potassium supplements for the prevention of hypokalemia is about 20 mEq daily, and the usual oral dosage of potassium for the treatment of potassium depletion is 40-100 mEq or more daily. However, it is important to remember that dosage must be individualized for each patient. Forty mEq of potassium is provided by approximately:

*3.9 g of potassium acetate

*4.0 g of potassium bicarbonate

*3.0 g of potassium chloride

*4.3 g of potassium citrate

*9.4 g of potassium gluconate

*5.4 g of monobasic potassium phosphate

*3.5 g of dibasic potassium phosphate

Oral potassium supplements are usually administered in 2-4 doses daily. To avoid serious hyperkalemia, replacement of potassium deficits must be undertaken gradually usually over a 3- to 7-day period depending on the severity of the deficit. Potassium dosage for adults should usually not exceed 150 mEq daily, and the dosage for young children should not exceed 3 mEq/kg daily. Close monitoring of the ECG and plasma potassium concentrations is essential during IV administration of potassium.

The acetate, bicarbonate, chloride, citrate, and gluconate salts of potassium are administered orally. Potassium chloride, potassium acetate, and potassium phosphate may be administered by slow IV infusion. Rarely, potassium-containing injections are given by hypodermoclysis, in which case potassium concentrations should not exceed 10 mEq/L in order to avoid local pain. Whenever possible, potassium supplements should be given orally since the relatively slow absorption from the GI tract prevents sudden, large increases in plasma potassium concentrations. Oral potassium supplements should preferably be administered as liquid with or after meals with a full glass of water or fruit juice to minimize the possibility of GI irritation and a saline cathartic effect. Enteric-coated (no longer commercially available in the US) and wax matrix tablets must be swallowed and not allowed to dissolve in the mouth. Other commercially available oral dosage forms of potassium should be dissolved and/or diluted and administered according to the instructions of the manufacturer.

Potassium for injection concentrates must be diluted with a compatible IV solution prior to administration. Diluted solutions of potassium acetate, potassium chloride, and potassium phosphate for injection concentrates must be administered slowly. Potassium injections should generally be administered only in patients with adequate urine flow. In dehydrated patients, 1 liter of potassium-free fluid should be administered prior to initiating potassium therapy. Generally, potassium concentrations in IV fluids should not exceed 40 mEq/L and the rate of administration should not exceed 20 mEq/hour. However, higher potassium concentrations (e.g., 60-80 mEq/L) administered more rapidly occasionally may be needed initially in cases of severe hypokalemia and associated cardiac arrhythmias or for the management of diabetic ketoacidosis or the diuretic phase of acute renal failure. Local vascular intolerance may limit the ability to administer such concentrated solutions. In such cases, use of a large vein with a relatively high blood flow (e.g., femoral vein) or splitting and administering the dose in less concentrated solutions via 2 veins simultaneously can be considered. Administration of such concentrated potassium solutions via a subclavian, jugular, or right atrial catheter should be avoided since local potassium concentrations achieved in the heart may be high and potentially cardiotoxic. The ECG should be monitored closely when the rate of IV potassium administration exceeds 20 mEq/hour. Peaking of the T wave or other ECG changes associated with hyperkalemia (see Cautions: Hyperkalemia) indicate that the rate of potassium infusion is excessive and should be reduced.

Viaflex(R) Plus containers of potassium chloride injections should be checked for minute leaks by firmly squeezing the bag. The injection should be discarded if the container seal is not intact or leaks are found or if the solution is cloudy or contains a precipitate. The injection in plastic containers should not be used in series connections with other plastic containers, since such use could result in air embolism from residual air being drawn from the primary container before administration of fluid from the secondary container is complete.

Oral administration of potassium supplements or ingestion of potassium-rich foods should replace IV potassium therapy as soon as possible.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.